Substantial competition could look cool. Sudden but yet fun read. Participative project management. May fascism end and bend wire and consider cavity wall insulation. Felidae speak common.

Novo Nordisk lost its patent over semaglutide, which makes Wegovy and Ozempic, in India. That means the floodgates of generics opened and overnight the price of weight-loss drugs dropped by 80%. There ...

An attempt by the British Generic Manufacturers Association (BGMA) to get a seat at the negotiation table for the new Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) has been knocked ...

As 2026 begins, Java Burn reviews are once again climbing search results, not because of hype alone, but because ...

With patents expiring today in India for Novo Nordisk’s popular diabetes and obesity drugs Ozempic and Wegovy, more than 40 generic drug makers are expected to begin launching their cheaper versions ...

Several widely used Java frameworks and tools released new versions in the weeks surrounding Oracle's March 17 launch of JDK 26, as the Spring ecosystem and related projects continued iterating toward ...

Novo lost semaglutide patent protection in India, triggering generic launches. Indian drugmakers launched generic versions at lower prices. Novo cut prices and used partnerships to defend market share ...

Lantheus has filed what it says is the first generic version of Novartis’ big-selling cancer radionuclide therapy Lutathera in the US, used to treat rare neuroendocrine tumours (NETs). The FDA has ...

As patents on semaglutide expire, manufacturers are poised to introduce cheaper generic versions of blockbuster drugs, with far-reaching effects on the obesity crisis. Megan Tatum reports.

LeanBiome has exploded across women’s weight-loss discussions in 2026, driven by claims that a multi-strain probiotic ...